Medication-assisted treatment (MAT) for opioid use disorder (OUD) has emerged as a key strategy for combatting the opioid epidemic. Controlled research has shown it to be more effective than abstinence programs in treating patients with the disorder (Connery, 2015). The ability of physicians and other healthcare professionals to use MAT for treatment of OUD was recently expanded through changes in federal legislation, but according to the Substance Abuse and Mental Health Services Administration (SAMSHA), MAT is greatly underused.
SAMHSA provides a concise overview of MAT and its potential benefits. Important points include:
While methadone must be administered through a SAMHSA-accredited Opioid Treatment Program, buprenorphine can be prescribed by a qualified physician, physician assistant, or nurse practitioner. MAT is safe for pregnant women, and “pregnant women on MAT are more likely to adhere to prenatal care and substance use treatment programs,” according to Mitra Ahadpour, M.D., DABAM, who is the deputy director of the FDA’s Center for Drug Evaluation and Research Office of Translational Sciences.
SAMHSA maintains an interactive map that provides locations and contact information for physicians across the country who provide buprenorphine in their practices.
“Medication and Counseling Treatment.” SAMHSA. https://www.samhsa.gov/medication-assisted-treatment/treatment
“CDER Conversation: Treatment for Opioid Use Disorder.” US Food and Drug Administration. https://www.fda.gov/Drugs/NewsEvents/ucm611659.htm
“Buprenorphine Treatment Practitioner Locator.” SAMHSA. https://www.samhsa.gov/medication-assisted-treatment/physician-program-data/treatment-physician-locator
Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015 Mar-Apr;23(2):63-75